odronextamab, and itepekimab. At the same time, when forecasting the growth rates of revenue and net income of the New York-based company, I took into account, among other things, the decline in ...

Video content above is prompted by the following: Thanks to all of you for this rich and informative discussion. Before we conclude, I’d like to get final thoughts from each of you.

Panelists discuss key gaps in communication between academic and community centers regarding the use of bispecifics and strategies to bridge them as well as best practices for ensuring a smooth ...

There are hundreds of items and equipment you can find throughout your playthrough of Kingdom Come: Deliverance 2 you can find throughout your journey. For those who don’t want to waste any time ...

We expect regulatory approvals for linvoseltamab in relapsed/refractory multiple myeloma, odronextamab in late-line follicular lymphoma, and the aforementioned Libtayo indication in adjuvant CSCC.

driven by the expanded labels of Eylea HD and Libtayo and by the potential launches of Ordspono (odronextamab), linvoseltamab, itepekimab, pozelimab/cemdisiran, and the novel oncology combination ...

The company is advancing several promising R&D programs, including pivotal data expected for Linvoseltamab in multiple myeloma and odronextamab in follicular lymphoma. Regeneron Pharmaceuticals ...

On December 9, REGN announced new and positive data for odronextamab monotherapy in patients with previously untreated follicular lymphoma with twelve abstracts spanning several B-cell non-Hodgkin ...